There’s plenty of growth in store for biotech and pharmaceuticals.
For one, by 2025, the sector could explode to a value of $727.1 billion, says Grand View Research.
Two, the sector is still one of the safest, most recession-proof investments around. Three, an aging population is demanding more treatments in an effort to live longer lives.
In addition, there’s also incredible new innovation in genetics and technology, creating new life-saving and life enhancing opportunities. Plus, big pharmaceutical companies are buying hot biotech companies to keep their pipelines full to avoid revenue shortfalls created by patent expirations.
As the sector heats up, here are two top favorites investors may want to keep an eye on.
Fate Therapeutics (FATE)
Oversold, Fate Therapeutics (FATE) could be a big winner.
While the stock has already run from nearly $12 to $76, there’s plenty to get excited about here. Most recently, the company announced “encouraging interim Phase 1 data from the Company’s off-the-shelf, iPSC-derived natural killer (NK) cell programs in relapsed / refractory acute myeloid leukemia (AML).”
According to Scott Wolchko, President and CEO, “We are highly encouraged by these Phase 1 data in patients with relapsed / refractory AML, which clearly indicate that off-the-shelf, iPSC-derived NK cells administered as monotherapy in the outpatient setting were well-tolerated, and have the potential to induce complete leukemic blast clearance in the bone marrow and confer durable remissions without further therapeutic intervention.”
TG Therapeutics (TGTX)
Oversold, TG Therapeutics is another hot biotech to consider.
“The company just announced that the U.S. Food and Drug Administration has accepted the Biologics License Application for ublituximab, the Company’s investigational glycoengineered anti-CD20 monoclonal antibody, in combination with UKONIQ, the Company’s once-daily, oral, inhibitor of PI3K-delta and CK1-epsilon, as a treatment for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL),” as noted in a recent press release.